Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical and Experimental Rheumatology|March 17, 2026
Cost effectiveness of avacopan for ANCA-associated vasculitis in ChinaYunong Jiang, Hanqiao Shao, Wenxi Tang
Health Economics Review|May 20, 2026
Economic evidence of alternative formulations and routes of administration for identical active pharmaceutical ingredient: a systematic reviewHanqiao Shao, Yunong Jiang, Mingye Zhao, et al.
BMC Cancer|February 8, 2024
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysisMingye Zhao, Taihang Shao, Hanqiao Shao, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 24, 2026
Comparing and Selecting Network Meta-Analysis Models for Cost-Effectiveness Analysis of Anticancer DrugsMingye Zhao, Taihang Shao, Hanqiao Shao, et al.
Cost Effectiveness and Resource Allocation : C/E|February 6, 2024
Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?Yusi Tu, Xiangyan Tang, Dachuang Zhou, et al.
JAMA Network Open|May 27, 2025
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic ReviewMingye Zhao, Taihang Shao, Yue Yin, et al.
BMC Public Health|January 21, 2025
Comparing the cost-benefit of breast cancer screening programs in rural and urban areas across four economic zones in China: a Markov modeling analysisDachuang Zhou, Kejia Zhou, Wenjuan Wang, et al.
Cost Effectiveness and Resource Allocation : C/E|September 18, 2024
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspectiveHanqiao Shao, Hongshu Fang, Yuan Li, et al.
BMC Medicine|January 11, 2024
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancerHanqiao Shao, Mingye Zhao, Ai-Jia Guan, et al.
Journal of Clinical Epidemiology|July 31, 2026
Estimating Overall Survival Treatment Effects in Oncology Trials: Hazard Ratio Instability and RMST as a Robust, Internally Predictive ComplementMingye Zhao, Taihang Shao, Hanqiao Shao, et al.
Pageof 2